Absence of Mortality Differences Between the First and Second COVID-19 Waves in Kidney Transplant Recipients

Berger, Bastien; Hazzan, Marc; Kamar, Nassim; François, H.; Matignon, Marie; Grèze, Clarisse; Gatault, Philippe; Frimat, Luc; Westeel, P. F.; Goutaudier, Valentin; Snanoudj, Renaud; Colosio, Charlotte; Sicard, A; Bertrand, Dominique; Mousson, Christiane; Bamoulid, Jamal; Thierry, Antoine; Anglicheau, Dany; Couzi, Lionel; Chemouny, Jonathan; Duveau, Agnès; Moal, Valérie; Meur, Yannick Le; Blancho, Gilles; Tourret, Jérôme; Malvezzi, Paolo; Mariat, Christophe; Bouvier, Nicolas; Caillard, Sophie; Thaunat, Olivier

doi:10.1016/j.ekir.2022.09.007

Cited by 5 publications

(2 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite changes in clinical practices based on recommendations derived from the general population, a study comparing the 60-d mortality rate caused by COVID-19 in KTRs showed no significant decrease between the first and second waves of the pandemic (25.3% versus 23.9%, respectively; P = 0.48). 5 This finding emphasized the need for dedicated clinical trials in SOT patients. Notably, a nationwide study has shed light on the positive impact of early usage of monoclonal antibodies (mAbs) in KTRs with mild COVID-19.…”

Section: Lessons Learned From the First Wavementioning

confidence: 99%

Challenges Faced by Solid Organ Transplant Recipients During the COVID-19 Pandemic in France: Historical Insights and Key Takeaways

Benotmane,

Legendre,

Caillard

2024

Transplantation

Self Cite

View full text Add to dashboard Cite

Section: Lessons Learned From the First Wavementioning

confidence: 99%

Challenges Faced by Solid Organ Transplant Recipients During the COVID-19 Pandemic in France: Historical Insights and Key Takeaways

Benotmane,

Legendre,

Caillard

2024

Transplantation

Self Cite

View full text Add to dashboard Cite

“…Patients with end stage kidney disease (ESKD) remain at high risk for COVID-19 morbidity and mortality due to their poor responses to vaccination and the high number of comorbidities, a condition that is particularly concerning for kidney transplant recipients (KTx). 1 , 2 Patients may obtain immunity against SARS-CoV2 through different ways, including active (vaccine or infection) or passive immunization anti-SARS-CoV2 antibodies, but no study has formally compared the efficacy of the various approaches in ESKD patients in renal replacement therapy (hemodialysis and kidney transplantation).…”

mentioning

confidence: 99%

Humoral and T cell Responses to SARS-CoV-2 Vaccine Booster and Anti-SARS-CoV-2 Monoclonal Antibodies in Patients With End-Stage Kidney Disease

Zaza

Stallone

Granata

et al. 2023

Kidney International Reports

View full text Add to dashboard Cite

Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)

Hilhorst

Bemelman

Bruchfeld

et al. 2023

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic led to rapid vaccine development and large global vaccination schemes. However, patients with immune-mediated kidney disease, chronic kidney diseases and kidney transplant recipients show high non-response rates to vaccination despite more than 3 vaccinations and, consequently, reduced viral clearance capacity when infected while receiving certain immunosuppressants, carrying an elevated risk for COVID-19 related morbidity and mortality. SARS-CoV-2 evolution has been characterized by the emergence of novel variants and spike mutations contributing to waning efficacy of neutralizing antibodies. To this end, the therapeutic field expands from vaccination towards a combined approach of immunization, pre-exposure prophylaxis and early post-exposure treatment using direct-acting antivirals and neutralizing monoclonal antibodies to treat early in the disease course and avoid hospitalization. This expert opinion paper from the Immunonephrology Working Group (IWG) of the European Renal Association (ERA) summarizes available prophylactic and/or early treatment options (i.e. neutralizing monoclonal antibodies and direct-acting antivirals) of SARS-CoV-2 infected patients with immune-mediated kidney disease, chronic kidney disease and kidney transplant recipients.

show abstract

Absence of Mortality Differences Between the First and Second COVID-19 Waves in Kidney Transplant Recipients

Cited by 5 publications

References 59 publications

Challenges Faced by Solid Organ Transplant Recipients During the COVID-19 Pandemic in France: Historical Insights and Key Takeaways

Challenges Faced by Solid Organ Transplant Recipients During the COVID-19 Pandemic in France: Historical Insights and Key Takeaways

Humoral and T cell Responses to SARS-CoV-2 Vaccine Booster and Anti-SARS-CoV-2 Monoclonal Antibodies in Patients With End-Stage Kidney Disease

Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)

Contact Info

Product

Resources

About